In the November issue of MedNousDr Paula Salmikangas, Dr Björn Carlsson and Dr Steffen Thirstrup address the risks and challenges of gene editing.


In recent years, gene editing technologies have moved from non-clinical tests into first in human clinical studies. Although it is still in the early days, there are currently a substantial number of ongoing early-stage clinical trials as well as encouraging single case reports demonstrating proof-of-concept.

In this article, Drs Paula Salmikangas, Björn Carlsson and Steffen Thirstrup examine the most common techniques to change the genome, the risk of tumour-formation and off-target editing.

Read More

The Authors

Dr Paula Salmikangas

Advisory Board Director

Read more

Dr Björn Carlsson

Principal Consultant / Advisory Board Member

Read more

Dr Steffen Thirstrup

LinkedIn

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.